05 aug 25   crystal amber fund - morphic medical inc. appoints new chief executive crystal amber fund ltd. | crs | 0 0 0.0% | mkt cap: 52.9m    rns number : 9143t crystal amber fund limited 05 august 2025   reach - a non-regulatory announcement 5 august 2025   crystal amber fund limited ("crystal amber fund", the "company" or the "fund")   morphic medical inc. appoints new chief executive   the board of crystal amber fund is pleased to announce that morphic medical inc. ("mmi"), the medical device company that has pioneered minimally invasive treatments of obesity and cardiometabolic disorders in which it owns 96.7% of the issued share capital has appointed mike gutteridge, most recently mmi's commercial director, as chief executive. mike brings a wealth of experience in the bariatric endoscopy space.   last month, crystal amber announced that mmi had received ce mark certification for its revolutionary reset® therapy, making this the first endoscopic, non-surgical treatment for both obesity and type 2 diabetes in europe. this ce designation, which ensures reset® has met all european commission safety, health and environmental protection requirements, allows access to treatment for the estimated 93 million patients in europe living with obesity and type 2 diabetes.   after five years and with ce mark now achieved, joe virgilio has stepped down as chief executive.    christopher waldron, chairman of crystal amber commented: "the board would like to thank joe for delivering ce mark and for all his efforts and commitment to innovation and patient care. the board is excited that mike, who brings a successful track record of international commercialisation, will be leading mmi as it enters a new and exciting stage of growth."    mike gutteridge commented: "i am honoured to become chief executive. with over thirty years in the medtech sector spanning clinical innovation, commercial strategy, market development and reimbursement, i am energised by the opportunity to lead morphic into its next phase, a focused expansion into global markets, accelerated commercialisation, and a deepening of our commitment to improving the lives of patients through effective durable therapies. this is an exciting time for our company, and i am proud to help shape what comes next."     for further enquiries please contact:   crystal amber fund limited chris waldron (chairman) tel: 01481 742 742 www.crystalamber.com   allenby capital limited - nominated adviser jeremy porter/ dan dearden-williams tel: 020 3328 5656   winterflood investment trusts - broker joe winkley/neil langford tel: 020 3100 0160   crystal amber advisers (uk) llp - investment adviser richard bernstein tel: 020 7478 9080   about reach announcements this is a reach announcement. reach is an investor communication service aimed at assisting listed and unlisted (including aim quoted) companies to distribute media only / non-regulatory news releases into the public domain. information required to be notified under the aim rules for companies, market abuse regulation or other regulation would be disseminated as an rns regulatory announcement and not on reach.     this information is provided by reach, the non-regulatory press release distribution service of rns, part of the london stock exchange. terms and conditions relating to the use and distribution of this information may apply. for further information, please contact rns@lseg.com or visit www.rns.com.  rns may use your ip address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. for further information about how rns and the london stock exchange use the personal data you provide us, please see our privacy policy.   end   nrazzggrvdggkzm return to news summary

Label: Gesunken